104 related articles for article (PubMed ID: 16782039)
1. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid.
Gomez SR; Xing DK; Corbel MJ; Coote J; Parton R; Yuen CT
Anal Biochem; 2006 Sep; 356(2):244-53. PubMed ID: 16782039
[TBL] [Abstract][Full Text] [Related]
2. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test.
Gomez SR; Yuen CT; Asokanathan C; Douglas-Bardsley A; Corbel MJ; Coote JG; Parton R; Xing DK
Vaccine; 2007 Apr; 25(17):3311-8. PubMed ID: 17287049
[TBL] [Abstract][Full Text] [Related]
3. Effect of different detoxification procedures on the residual pertussis toxin activities in vaccines.
Yuen CT; Asokanathan C; Cook S; Lin N; Xing D
Vaccine; 2016 Apr; 34(18):2129-34. PubMed ID: 26973066
[TBL] [Abstract][Full Text] [Related]
4. Reporter cell lines for detection of pertussis toxin in acellular pertussis vaccines as a functional animal-free alternative to the in vivo histamine sensitization test.
Hoonakker ME; Verhagen LM; van der Maas L; Sloots A; Hendriksen CFM
Vaccine; 2017 Feb; 35(8):1152-1160. PubMed ID: 28129894
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the carbohydrate binding and ADP-ribosyltransferase activities of chemically detoxified pertussis toxins.
Oh H; Kim BG; Nam KT; Hong SH; Ahn DH; Choi GS; Kim H; Hong JT; Ahn BY
Vaccine; 2013 Jun; 31(29):2988-93. PubMed ID: 23664992
[TBL] [Abstract][Full Text] [Related]
6. Modified binding assay for improved sensitivity and specificity in the detection of residual pertussis toxin in vaccine preparations.
Isbrucker RA; Bliu A; Prior F
Vaccine; 2010 Mar; 28(15):2687-92. PubMed ID: 20123053
[TBL] [Abstract][Full Text] [Related]
7. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
Xing D; Canthaboo C; Douglas-Bardsley A; Yuen CT; Prior S; Liu Y; Corbel M
Dev Biol (Basel); 2002; 111():57-68. PubMed ID: 12678225
[TBL] [Abstract][Full Text] [Related]
8. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay.
Yuen CT; Canthaboo C; Menzies JA; Cyr T; Whitehouse LW; Jones C; Corbel MJ; Xing D
Vaccine; 2002 Nov; 21(1-2):44-52. PubMed ID: 12443661
[TBL] [Abstract][Full Text] [Related]
9. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
Seubert A; D'Oro U; Scarselli M; Pizza M
Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
[TBL] [Abstract][Full Text] [Related]
10. Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.
Markey K; Asokanathan C; Feavers I
Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31319496
[TBL] [Abstract][Full Text] [Related]
11. Towards replacement of the acellular pertussis vaccine safety test: Comparison of in vitro cytotoxic activity and in vivo activity in mice.
Wagner LD; Corvette LJ; Ngundi MM; Burns DL
Vaccine; 2017 Dec; 35(51):7160-7165. PubMed ID: 29122386
[TBL] [Abstract][Full Text] [Related]
12. Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.
Ausar SF; Zhu S; Duprez J; Cohen M; Bertrand T; Steier V; Wilson DJ; Li S; Sheung A; Brookes RH; Pedyczak A; Rak A; Andrew James D
Commun Biol; 2020 Aug; 3(1):427. PubMed ID: 32759959
[TBL] [Abstract][Full Text] [Related]
13. Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.
Kimura A; Mountzouros KT; Schad PA; Cieplak W; Cowell JL
Infect Immun; 1990 Oct; 58(10):3337-47. PubMed ID: 2119344
[TBL] [Abstract][Full Text] [Related]
14. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
Robbins JB; Schneerson R; Keith JM; Shiloach J; Miller M; Trollors B
Vaccine; 2007 Apr; 25(15):2811-6. PubMed ID: 17291636
[TBL] [Abstract][Full Text] [Related]
15. Pertussis toxin B-oligomer suppresses human immunodeficiency virus-1 Tat-induced neuronal apoptosis through feedback inhibition of phospholipase C-beta by protein kinase C.
Jajoo S; Mukherjea D; Brewer GJ; Ramkumar V
Neuroscience; 2008 Jan; 151(2):525-32. PubMed ID: 18093742
[TBL] [Abstract][Full Text] [Related]
16. Hydrophobic binding of pertussis toxin is enhanced by oligosaccharide receptors.
Spangler BD; Heerze LD; Clark CG; Armstrong GD
Arch Biochem Biophys; 1993 Aug; 305(1):153-8. PubMed ID: 7688202
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of pertussis toxin B-oligomer.
Wong WS; Rosoff PM
Can J Physiol Pharmacol; 1996 May; 74(5):559-64. PubMed ID: 8884020
[TBL] [Abstract][Full Text] [Related]
18. The cAMP assay: a functional in vitro alternative to the in vivo Histamine Sensitization test.
Hoonakker ME; Ruiterkamp N; Hendriksen CF
Vaccine; 2010 Feb; 28(5):1347-52. PubMed ID: 19941995
[TBL] [Abstract][Full Text] [Related]
19. Specificity and detection limit of a dermal temperature histamine sensitization test for absence of residual pertussis toxin in vaccines.
Jensen SE; Illigen KE; Badsberg JH; Hasløv KR
Biologicals; 2012 Jan; 40(1):36-40. PubMed ID: 22000164
[TBL] [Abstract][Full Text] [Related]
20.
Hoonakker ME
Toxins (Basel); 2021 Aug; 13(8):. PubMed ID: 34437436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
